4.90
3.35%
-0.17
Handel nachbörslich:
4.90
Finanzdaten der Nuvectis Pharma Inc-Aktie (NVCT)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Research and Development |
37.63%
2.66
|
4.265 | 4.486 | 4.262 | 2.367 |
Operating Income/Loss |
35.97%
-4.396
|
-6.866 | -6.158 | -5.772 | -4.101 |
Income/Loss From Continuing Operations Before Tax |
37.01%
-4.171
|
-6.622 | -5.881 | -5.708 | -4.049 |
Income/Loss From Continuing Operations After Tax |
37.01%
-4.171
|
-6.622 | -5.881 | -5.708 | -4.049 |
Net Income/Loss
|
37.01%
-4.171
|
-6.622 | -5.881 | -5.708 | -4.049 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
7,603%
16.56
|
0.215 | 16.10 | 15.18 | 14.72 |
Diluted Average Shares |
7,603%
16.56
|
0.215 | 16.10 | 15.18 | 14.72 |
Basic Earnings Per Share |
39.02%
-0.25
|
-0.41 | -0.37 | -0.38 | -0.27 |
Diluted Earnings Per Share |
39.02%
-0.25
|
-0.41 | -0.37 | -0.38 | -0.27 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):